Download this free whitepaper to learn more.
This white paper delves into the use of inclusion bodies within biopharmaceutical production, which have gone from historically being considered undesirable byproducts of microbial expression systems to eventually gaining attention for their potential in producing a range of difficult to express proteins in E. coli systems. The author highlights the advantages of insoluble expression and address the challenges associated with purification. Also presented is FUJIFILM Biotechnologies’ approach to developing and scaling up these types of processes for a diverse range of biologics.
Offered Free by: FUJIFILM Biotechnologies
See All Resources from: FUJIFILM Biotechnologies
